Bubble or no bubble, this is the best stock for AI exposure: analyst
Investing.com - Oppenheimer lowered its price target on Perspective Therapeutics Inc (NYSE:CATX) to $13.00 from $14.00 while maintaining an Outperform rating on the stock. The revised target still suggests significant upside from the current price of $2.22, with analyst consensus remaining strongly bullish at 1.33 (Strong Buy).
The price target reduction follows Perspective Therapeutics’ third-quarter business update released Monday, and comes after the company’s shares fell 29% on the same day when competitor Sanofi/Oranomed presented updated Alphamedix02 results showing a 60% objective response rate (ORR). This recent volatility adds to CATX’s challenging price performance, with the stock down nearly 80% over the past year.
Perspective Therapeutics recently reported positive results for its VMT-α-NET treatment at ESMO with a 35% ORR, significantly lower than the competing therapy’s reported efficacy.
Oppenheimer noted that key differences between the studies, including patient population, follow-up period, safety, and dosing strategy, make this "a more competitive story than the headline numbers suggest," maintaining a cautiously optimistic outlook.
The company reported $174 million in cash as of the third quarter of 2025, with meaningful clinical updates anticipated across its portfolio during 2026, including potential data from 35 patients in the VMT-α-NET trial expected in early 2026.
In other recent news, Perspective Therapeutics Inc has been the focus of several key developments. The company presented updated interim data from its ongoing Phase 1/2a clinical trial of its cancer treatment, [212Pb]VMT-α-NET, at the European Society for Medical Oncology Congress 2025. The trial showed an objective response rate of 44% in Cohort 2, with 14 out of 16 patients remaining free from progression. Despite this, the market seemed to have anticipated stronger results. BTIG initiated coverage on Perspective Therapeutics with a Buy rating and set a price target of $14, recognizing the company’s leadership in next-generation radiopharmaceuticals. Additionally, H.C. Wainwright reiterated its Buy rating and $10 price target, following the treatment of the first patient in a new cohort of the company’s dose-finding trial. UBS maintained its Buy rating and $18 price target after the company reported progress in its VMT-a-NET trial for neuroendocrine tumors. However, Oppenheimer adjusted its price target from $15 to $14, while maintaining an Outperform rating, following the company’s recent clinical updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.